Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Nature communications - 22 Nov 2017

Di Tullio Alessandro, Rouault-Pierre Kevin, Abarrategi Ander, Mian Syed, Grey William, Gribben John, Stewart Aengus, Blackwood Elizabeth, Bonnet Dominique

Abstract excerpt

Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances AraC-mediated killing of AML cells both in vitro and in vivo, thus abrogating any potential chemoresistance mechanisms involving DNA repair. Importantly, this combination of drugs does not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to Cytarabine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Granulocyte Colony-Stimulating Factor

Share to HL-60 Cells

Share to Mice, Inbred NOD

Share to Piperidines

Share to Pyrroles

Share to U937 Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 29162833
DOI: 10.1038/s41467-017-01834-4
PMCID: PMC5698422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.PMID 29162833Read ↗

CHK1 as a therapeutic target to bypass chemoresistance in AMLSemantic proximity Read ↗

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting TherapySemantic proximity Read ↗

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated CytotoxicitySemantic proximity Read ↗

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cellsSemantic proximity Read ↗

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cellsSemantic proximity Read ↗

Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.Semantic proximity Read ↗

Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.Semantic proximity Read ↗

Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cellsSemantic proximity Read ↗

Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.Semantic proximity Read ↗

Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.Semantic proximity Read ↗

Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.Semantic proximity Read ↗

<i>In vivo</i> mechanisms of resistance to cytarabine in acute myeloid leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.